FGFR2 and biliary tract neoplasm: Ponatinib was further evaluated in patients (n = 12) with advanced biliary tract cancer (83.3% iCCA; 16.7% gallbladder) with FGFR2 alterations (83.3% FGFR2 translocations) who received prior chemotherapy.